GNTA Genenta Science S.p.A.
Price Chart
Executive Summary
Genenta Science completed the acquisition of the remaining 80.5% of A.T.C. S.r.l. for €9.6M, paid via the issuance of 24.6M new ordinary shares at €0.39/share to the ATC shareholders. The ATC shareholders received shares subject to a 36-month lock-up, with put/call options at +/-30% of the issue price. This transaction consolidates full ownership of ATC and eliminates prior milestone-based tranches, but results in significant dilution for existing GNTA shareholders.
Actionable Insight
The acquisition consolidates ATC but at a steep dilution cost (~53% increase in shares outstanding). The €0.39/share issue price is well below the current market price (implied ~$1.00), creating a potential overhang. The put/call options create a floor at ~€0.27 and a cap at ~€0.51 for the ATC shareholders' shares, but the lock-up prevents near-term selling. Monitor for any operational updates from ATC that could justify the dilution.
Key Facts
- Genenta acquired the remaining 80.5% of A.T.C. S.r.l. for an aggregate purchase price of €9,604,076.82.
- The purchase price was satisfied by set-off against the ATC shareholders' subscription of 24,625,838 new Genenta ordinary shares at €0.39 per share.
- The transaction was completed on May 29, 2026.
- The new shares are subject to a 36-month lock-up period.
- ATC shareholders were granted a put option (years 3-5) if GNTA stock falls >30% below €0.39; Genenta has a call option (years 1-3) if stock rises >30% above €0.39.
- Genenta now holds 100% of ATC's corporate capital.
- Prior milestone-based tranches (Second and Third Tranche of the Capital Increase) and the original Investor Put Option Rights under the Investment Agreement were superseded.
Financial Impact
€9.6M acquisition paid via 24.6M new shares (€0.39/share), representing ~53% dilution based on pre-deal share count (implied from 24.6M new shares vs. ~46M pre-deal market cap at $46M / ~$1.00/share).
Risk Factors
- Significant dilution: 24.6M new shares issued, likely increasing share count by over 50%.
- The €0.39/share issue price is below current trading levels, potentially pressuring the stock.
- Put option at €0.27 (30% below issue price) creates a contingent liability if GNTA stock declines.
- No financial details on ATC's revenue or profitability were disclosed, making it difficult to assess the value of the acquisition.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-026354 |
| Document: form6-k.htm | 0001493152-26-026354 |
| Document: 0001493152-26-026354-index-headers.html | 0001493152-26-026354 |
| Document: 0001493152-26-026354-index.html | 0001493152-26-026354 |
| Document: 0001493152-26-026354.txt | 0001493152-26-026354 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
16d ago
|
6-K
| $1.65 $2.04 | ▲ +23.64% | ▲ +26.39% | $1.87 (+13.33%) |
|
Apr 23, 2026
7w ago
|
6-K
| $0.7080 $0.7110 | ▲ +0.42% | ▼ −0.49% | $1.87 (+164.12%) |
|
Apr 14, 2026
8w ago
|
6-K
| $0.7140 $0.7140 | · 0.00% | ▲ +1.64% | $1.87 (−161.90%) |
|
Mar 27, 2026
11w ago
|
Press Release
| $0.7100 $0.6750 | ▼ −4.93% | ▼ −8.79% | $1.87 (+163.38%) |
|
Mar 13, 2026
13w ago
|
Press Release
| $0.8800 $0.6310 | ▼ −28.30% | ▼ −26.18% | $1.87 (+112.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access